Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
In this dose-ranging study 220 seniors who had received the 23-valent pneumococcal polysaccharide (PnPS) vaccine at least 5 years prior to enrollment were assigned to receive one of four volumes (0.1, 0.5, 1 or 2 ml) of 7-valent pneumococcal conjugate (PnC) vaccine or a 0.5 ml dose of 23-valent PnPS vaccine. All participants received a reduced challenge dose of 0.1 ml of PnPS vaccine 1 year after enrollment. There was evidence of a dose response to PnC vaccine and antibody levels in the 1 ml PnC group tended to be significantly higher than in the PnPS group. A booster response to the challenge vaccination was not observed. Administration of a 1 ml dose of PnC vaccine is more immunogenic than 0.5 ml of PnPS vaccine in elderly adults previously vaccinated with PnPS vaccine.
Jackson
Lisa A
LA
Group Health Center for Health Studies, 1730 Minor Ave, Ste 1600, Seattle, WA 98101, USA. Jackson.L@ghc.org
Neuzil
Kathleen M
KM
Nahm
Moon H
MH
Whitney
Cynthia G
CG
Yu
Onchee
O
Nelson
Jennifer C
JC
Starkovich
Pat T
PT
Dunstan
Maya
M
Carste
Barbara
B
Shay
David K
DK
Baggs
James
J
Carlone
George M
GM
D000368:Aged; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000097:blood; D004306:Dose-Response Relationship, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D008297:Male; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000009:adverse effects
D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines